JP2017515909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515909A5 JP2017515909A5 JP2017512461A JP2017512461A JP2017515909A5 JP 2017515909 A5 JP2017515909 A5 JP 2017515909A5 JP 2017512461 A JP2017512461 A JP 2017512461A JP 2017512461 A JP2017512461 A JP 2017512461A JP 2017515909 A5 JP2017515909 A5 JP 2017515909A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- formulation according
- seq
- concentration
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461994427P | 2014-05-16 | 2014-05-16 | |
| US61/994,427 | 2014-05-16 | ||
| US201462093734P | 2014-12-18 | 2014-12-18 | |
| US62/093,734 | 2014-12-18 | ||
| US201462095181P | 2014-12-22 | 2014-12-22 | |
| US62/095,181 | 2014-12-22 | ||
| PCT/IB2015/053602 WO2015173782A1 (en) | 2014-05-16 | 2015-05-15 | Antibody formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020035298A Division JP7277681B2 (ja) | 2014-05-16 | 2020-03-02 | 抗体処方物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515909A JP2017515909A (ja) | 2017-06-15 |
| JP2017515909A5 true JP2017515909A5 (enExample) | 2018-06-28 |
| JP6707528B2 JP6707528B2 (ja) | 2020-06-10 |
Family
ID=53200250
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512461A Active JP6707528B2 (ja) | 2014-05-16 | 2015-05-15 | 抗体処方物 |
| JP2020035298A Active JP7277681B2 (ja) | 2014-05-16 | 2020-03-02 | 抗体処方物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020035298A Active JP7277681B2 (ja) | 2014-05-16 | 2020-03-02 | 抗体処方物 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10556009B2 (enExample) |
| EP (3) | EP3719038A1 (enExample) |
| JP (2) | JP6707528B2 (enExample) |
| KR (2) | KR102501602B1 (enExample) |
| AU (1) | AU2015260758B2 (enExample) |
| BR (1) | BR112016026811A2 (enExample) |
| CA (1) | CA2949212C (enExample) |
| DK (1) | DK3143047T3 (enExample) |
| ES (1) | ES2927990T3 (enExample) |
| IL (1) | IL248802B (enExample) |
| MX (1) | MX381232B (enExample) |
| MY (1) | MY185802A (enExample) |
| SG (1) | SG11201609622PA (enExample) |
| TW (1) | TWI694836B (enExample) |
| WO (1) | WO2015173782A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| ES2964713T3 (es) | 2014-10-23 | 2024-04-09 | Amgen Inc | Reducción de la viscosidad de formulaciones farmacéuticas |
| CN109562149A (zh) * | 2016-08-05 | 2019-04-02 | 德国杰特贝林生物制品有限公司 | C1酯酶抑制剂的药物制剂 |
| KR102585976B1 (ko) | 2016-08-17 | 2023-10-05 | 컴퓨젠 엘티디. | 항-tigit 항체, 항-pvrig 항체 및 이들의 조합 |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| US10093731B2 (en) * | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| US10493149B2 (en) * | 2017-04-11 | 2019-12-03 | Kiniksa Pharmaceuticals, Ltd. | Stable anti-OSMR antibody formulation |
| CA3061279A1 (en) * | 2017-05-16 | 2018-11-22 | Octapharma Ag | C1-esterase inhibitor preparation |
| AU2019254483B2 (en) | 2018-04-16 | 2025-02-27 | Merck Patent Gmbh | Viscosity reduction of highly concentrated protein formulations |
| JP7641908B2 (ja) * | 2019-03-29 | 2025-03-07 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用 |
| CA3160207A1 (en) * | 2019-11-06 | 2021-05-14 | Novartis Ag | Treatment for sjogren's syndrome |
| KR20230006824A (ko) | 2020-04-24 | 2023-01-11 | 킹스칼리지런던 | Ige 항체를 포함하는 조성물 |
| GB202006093D0 (en) | 2020-04-24 | 2020-06-10 | King S College London | Composition |
| WO2021249664A1 (en) * | 2020-06-12 | 2021-12-16 | Glaxosmithkline Intellectual Property Management Limited | Anti-blys antibody for treating proteinuric kidney disease |
| KR20230110304A (ko) | 2020-11-18 | 2023-07-21 | 아스트라제네카 아베 | 스테로이드 절약 |
| US20240301031A1 (en) | 2021-03-31 | 2024-09-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Truncated taci polypeptide and fusion protein and use thereof |
| WO2022223028A1 (zh) * | 2021-04-23 | 2022-10-27 | 上海君实生物医药科技股份有限公司 | 抗BLyS抗体、其药物组合物及其用途 |
| BR112023024657A2 (pt) * | 2021-06-17 | 2024-02-20 | Glaxosmithkline Intellectual Property Ltd | Anticorpos anti-baff para uso em um método de tratamento de covid longo e/ou sequelas agudas pós-infecção por sars-cov2 (pasc) |
| AU2022317215A1 (en) | 2021-07-27 | 2024-02-29 | Astrazeneca Ab | Treatment of lupus |
| CA3239182A1 (en) * | 2022-05-23 | 2023-11-30 | Zhipeng SU | Stable antibody preparation |
| TW202440636A (zh) | 2023-03-21 | 2024-10-16 | 美商傳記５５有限公司 | Ｃｄ１９／ｃｄ３８多特異性抗體 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| AU2002319544B2 (en) | 2001-08-10 | 2008-07-10 | Aberdeen University | Antigen binding domains from fish |
| AR035119A1 (es) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| US20030138417A1 (en) * | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| ES2379267T3 (es) * | 2003-10-23 | 2012-04-24 | Novartis Vaccines And Diagnostics, Inc. | Composiciones estabilizadas |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| KR20080074120A (ko) * | 2005-10-13 | 2008-08-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물 |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| WO2011160086A2 (en) * | 2010-06-18 | 2011-12-22 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system |
| WO2012076670A2 (en) * | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| JP6176849B2 (ja) * | 2011-07-19 | 2017-08-09 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
| US20150239970A1 (en) | 2012-10-25 | 2015-08-27 | Medimmune, Llc | Stable, Low Viscosity Antibody Formulation |
| WO2014114651A1 (en) * | 2013-01-24 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Tnf-alpha antigen-binding proteins |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| US9762377B2 (en) | 2015-09-29 | 2017-09-12 | Cable Television Laboratories, Inc. | Hybrid full duplex communications in a radio frequency cable network |
-
2015
- 2015-05-14 TW TW104115341A patent/TWI694836B/zh active
- 2015-05-15 CA CA2949212A patent/CA2949212C/en active Active
- 2015-05-15 EP EP20150351.3A patent/EP3719038A1/en active Pending
- 2015-05-15 KR KR1020227036947A patent/KR102501602B1/ko active Active
- 2015-05-15 US US15/311,223 patent/US10556009B2/en active Active
- 2015-05-15 KR KR1020167034853A patent/KR20170005099A/ko not_active Ceased
- 2015-05-15 MX MX2016015006A patent/MX381232B/es unknown
- 2015-05-15 MY MYPI2016704190A patent/MY185802A/en unknown
- 2015-05-15 AU AU2015260758A patent/AU2015260758B2/en not_active Ceased
- 2015-05-15 EP EP19185861.2A patent/EP3715371A1/en not_active Withdrawn
- 2015-05-15 ES ES15724070T patent/ES2927990T3/es active Active
- 2015-05-15 DK DK15724070.6T patent/DK3143047T3/da active
- 2015-05-15 BR BR112016026811A patent/BR112016026811A2/pt not_active Application Discontinuation
- 2015-05-15 EP EP15724070.6A patent/EP3143047B8/en active Active
- 2015-05-15 SG SG11201609622PA patent/SG11201609622PA/en unknown
- 2015-05-15 JP JP2017512461A patent/JP6707528B2/ja active Active
- 2015-05-15 WO PCT/IB2015/053602 patent/WO2015173782A1/en not_active Ceased
-
2016
- 2016-11-07 IL IL248802A patent/IL248802B/en active IP Right Grant
-
2018
- 2018-06-13 US US16/007,102 patent/US20180289804A1/en not_active Abandoned
-
2020
- 2020-01-07 US US16/736,042 patent/US11179463B2/en active Active
- 2020-03-02 JP JP2020035298A patent/JP7277681B2/ja active Active
-
2021
- 2021-11-05 US US17/519,606 patent/US12296007B2/en active Active
-
2025
- 2025-04-11 US US19/176,498 patent/US20250249095A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504032A5 (enExample) | ||
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2015522252A5 (enExample) | ||
| JP2020524661A5 (enExample) | ||
| JP2015120706A5 (enExample) | ||
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| JP2018521638A5 (enExample) | ||
| JP2020518598A5 (enExample) | ||
| JP2020518600A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| JP2011528902A5 (enExample) | ||
| JP2019510739A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2018535650A5 (enExample) | ||
| PE20090769A1 (es) | Proteinas de union a antigenos que se unen a par-2 | |
| JP2016539096A5 (enExample) | ||
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| JP2018536393A5 (enExample) | ||
| JP2016519650A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
| RU2018112861A (ru) | Стабильные антитела, связывающиеся с несколькими антигенами |